You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業(02616.HK)與艾力斯簽訂RET抑製劑普吉華於內地商業化推廣協議
阿思達克 11-09 11:25
基石藥業(02616.HK)宣布,將RET抑製劑普吉華(R)(普拉替尼膠囊)的內地獨家商業化推廣權授予上海艾力斯醫藥科技股份有限公司(688578.SH)。基石藥業繼續擁有普吉華(R)在內地研發、註冊等推廣權之外的權益。 根據協議條款,基石藥業將獲得首付款和後續的研發里程碑付款,並將繼續獲得普吉華(R)在內地的銷售收入,艾力斯將從基石藥業收取服務費。 普吉華(R)是中國首款獲批上市的精準靶向RET靶點的選擇性抑製劑。目前,普吉華(R)在美國和中國均已獲得一線、二線非小細胞肺癌適應症的完全批准,同時覆蓋甲狀腺癌。(ca/u) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account